[Biologic and clinical relevance of cytogenetic analysis in primary myelodysplastic syndromes].
Cytogenetic abnormalities in myelodysplastic syndromes (MDS) are complex and heterogeneous. The most frequent rearrangements (gains or losses of genetic material) vary from patient to patient, and within the same patient. The prognostic value of these rearrangements has been extensively studied. They allowed the definition of a risk based classification system for MDS (the International Scoring System for evaluating Prognosis, IPSS), proven to be a highly useful method for evaluating prognosis in MDS patients. Despite recent progress in mapping and definition of minimally deleted chromosomal regions, the primary critical genetic events remain to be determined. The recurrent cytogenetic abnormalities associated with MDS are likely to be secondary events contributing to but not initiating the neoplastic phenotype of the disease.
Raynaud
S D
SD
Unité de cytogénétique des hémopathies malignes, hôpital de l'Archet, BP 79, 06202 Nice, France. raynaud@naxos.unice.fr
D002869:Chromosome Aberrations; D002874:Chromosome Mapping; D020732:Cytogenetic Analysis; D017353:Gene Deletion; D020022:Genetic Predisposition to Disease; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000235:genetics*; D011379:Prognosis; D014178:Translocation, Genetic